Immunovant, Inc. IMVT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s financing cash flow?
- Immunovant, Inc. (IMVT) reported financing cash flow of $3.64M in Q1 2026.
- How has Immunovant, Inc.'s financing cash flow changed year-over-year?
- Immunovant, Inc.'s financing cash flow decreased by 99.2% year-over-year, from $450.61M to $3.64M.
- What is the long-term trend for Immunovant, Inc.'s financing cash flow?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s financing cash flow has grown at a 103.3% compound annual growth rate (CAGR), from $70.89M to $595.76M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.